{"id":"https://openalex.org/W2891699786","doi":"https://doi.org/10.1007/s40121-018-0211-4","title":"Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials","display_name":"Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials","publication_year":2018,"publication_date":"2018-09-21","ids":{"openalex":"https://openalex.org/W2891699786","doi":"https://doi.org/10.1007/s40121-018-0211-4","mag":"2891699786","pmid":"https://pubmed.ncbi.nlm.nih.gov/30242736","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6249184"},"language":"en","primary_location":{"id":"doi:10.1007/s40121-018-0211-4","doi":"https://doi.org/10.1007/s40121-018-0211-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40121-018-0211-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40121-018-0211-4.pdf","source":{"id":"https://openalex.org/S2739130986","display_name":"Infectious Diseases and Therapy","issn_l":"2193-6382","issn":["2193-6382","2193-8229"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Infectious Diseases and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s40121-018-0211-4.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104045162","display_name":"Gregory J. Moran","orcid":"https://orcid.org/0009-0008-1566-1668","observed_orcids":["https://orcid.org/0009-0008-1566-1668"]},"institutions":[{"id":"https://openalex.org/I4210130891","display_name":"Olive View-UCLA Medical Center","ror":"https://ror.org/03b66rp04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1328359107","https://openalex.org/I4210130891"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory J. Moran","raw_affiliation_strings":["Division of Infectious Diseases, Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Diseases, Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA","institution_ids":["https://openalex.org/I4210130891"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041634768","display_name":"Carisa S. De Anda","orcid":"https://orcid.org/0000-0002-6344-8123","observed_orcids":["https://orcid.org/0000-0002-6344-8123"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Carisa De Anda","raw_affiliation_strings":["MRL, Merck & Co., Inc., Kenilworth, NJ, USA. carisa.de.anda@merck.com","MRL, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MRL, Merck & Co., Inc., Kenilworth, NJ, USA. carisa.de.anda@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"MRL, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102453918","display_name":"Anita Das","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita F. Das","raw_affiliation_strings":["Department of Biostatistics, InClin, San Mateo, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, InClin, San Mateo, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010952579","display_name":"Sinikka Green","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sinikka Green","raw_affiliation_strings":["eStudySite, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"eStudySite, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109161729","display_name":"Purvi Mehra","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Purvi Mehra","raw_affiliation_strings":["Artemis Institute for Clinical Research, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Artemis Institute for Clinical Research, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065714006","display_name":"Philippe Prokocimer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Prokocimer","raw_affiliation_strings":["MRL, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MRL, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5041634768"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":1.7178,"has_fulltext":true,"cited_by_count":16,"citation_normalized_percentile":{"value":0.83453341,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"7","issue":"4","first_page":"509","last_page":"522"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.8095999956130981,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.8095999956130981,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11153","display_name":"Streptococcal Infections and Treatments","score":0.03519999980926514,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.0340999998152256,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tedizolid","display_name":"tedizolid","score":0.9679999947547913},{"id":"https://openalex.org/keywords/linezolid","display_name":"linezolid","score":1.0},{"id":"https://openalex.org/keywords/acute-bacterial-skin-and-skin-structure-infections","display_name":"acute bacterial skin and skin structure infections","score":0.9860000014305115},{"id":"https://openalex.org/keywords/people-who-inject-drugs","display_name":"people who inject drugs","score":0.9940000176429749},{"id":"https://openalex.org/keywords/oxazolidinones","display_name":"oxazolidinones","score":0.9940000176429749},{"id":"https://openalex.org/keywords/staphylococcus-aureus","display_name":"Staphylococcus aureus","score":0.9710000157356262},{"id":"https://openalex.org/keywords/wound-infection","display_name":"wound infection","score":0.7699999809265137},{"id":"https://openalex.org/keywords/cellulitis","display_name":"cellulitis","score":0.875},{"id":"https://openalex.org/keywords/erysipelas","display_name":"erysipelas","score":0.9739999771118164},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8410000205039978},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.8899999856948853},{"id":"https://openalex.org/keywords/emergency-department-care","display_name":"emergency department care","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9296351671218872},{"id":"https://openalex.org/C2781414143","wikidata":"https://www.wikidata.org/wiki/Q411377","display_name":"Linezolid","level":5,"score":0.8778132200241089},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6554137468338013},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5911307334899902},{"id":"https://openalex.org/C2775983603","wikidata":"https://www.wikidata.org/wiki/Q2458539","display_name":"Skin infection","level":4,"score":0.5151609182357788},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4466026723384857},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35187092423439026},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34210091829299927},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3110484480857849},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.10907590389251709},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.08664017915725708},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.06036528944969177},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.1007/s40121-018-0211-4","doi":"https://doi.org/10.1007/s40121-018-0211-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40121-018-0211-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40121-018-0211-4.pdf","source":{"id":"https://openalex.org/S2739130986","display_name":"Infectious Diseases and Therapy","issn_l":"2193-6382","issn":["2193-6382","2193-8229"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Infectious Diseases and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5246939","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6249184","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6249184","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6249184","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Infect Dis Ther","raw_type":"Text"},{"id":"pmid:30242736","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30242736","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Infectious diseases and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:8fffaf047c8b41cdb351987a187cf09e","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/8fffaf047c8b41cdb351987a187cf09e","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Infectious Diseases and Therapy, Vol 7, Iss 4, Pp 509-522 (2018)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s40121-018-0211-4","doi":"https://doi.org/10.1007/s40121-018-0211-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40121-018-0211-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40121-018-0211-4.pdf","source":{"id":"https://openalex.org/S2739130986","display_name":"Infectious Diseases and Therapy","issn_l":"2193-6382","issn":["2193-6382","2193-8229"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Infectious Diseases and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320318975","display_name":"Nabriva Therapeutics","ror":"https://ror.org/017ax4r20"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2891699786.pdf","grobid_xml":"https://content.openalex.org/works/W2891699786.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1674662420","https://openalex.org/W1970780793","https://openalex.org/W1993786022","https://openalex.org/W2006923511","https://openalex.org/W2033667948","https://openalex.org/W2039989497","https://openalex.org/W2041509233","https://openalex.org/W2056127182","https://openalex.org/W2057599352","https://openalex.org/W2073818453","https://openalex.org/W2081837424","https://openalex.org/W2085981430","https://openalex.org/W2094052917","https://openalex.org/W2101368910","https://openalex.org/W2102327712","https://openalex.org/W2106330783","https://openalex.org/W2106779858","https://openalex.org/W2108106379","https://openalex.org/W2114002456","https://openalex.org/W2114067614","https://openalex.org/W2122633654","https://openalex.org/W2123778879","https://openalex.org/W2139806006","https://openalex.org/W2145186654","https://openalex.org/W2145514220","https://openalex.org/W2145558739"],"related_works":["https://openalex.org/W2201444756","https://openalex.org/W2935712984","https://openalex.org/W2972051624","https://openalex.org/W2777585435","https://openalex.org/W2591723352","https://openalex.org/W4415300223","https://openalex.org/W2039989497","https://openalex.org/W2303185686","https://openalex.org/W2513411535","https://openalex.org/W2913315702"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Injection":[1],"drug":[2],"users":[3],"(IDUs)":[4],"often":[5],"develop":[6],"acute":[7],"bacterial":[8],"skin":[9,11],"and":[10,15,39,112,162,166,170,172,204,225,229,240],"structure":[12],"infections":[13,138],"(ABSSSI)":[14],"use":[16,244],"emergency":[17],"departments":[18],"as":[19],"their":[20],"primary":[21],"source":[22],"for":[23,160,174],"medical":[24],"care.":[25],"METHODS:":[26],"A":[27],"post":[28],"hoc":[29],"subgroup":[30],"analysis":[31],"of":[32,41,46,192,211,227,234,245],"two":[33,57],"randomized":[34],"trials":[35,61],"examined":[36],"the":[37,44,116,232,243],"efficacy":[38],"safety":[40,226],"tedizolid":[42,76,161,202,217,228],"in":[43,48,64,98,126,134,154,168,197,231,238,247,250],"treatment":[45,189,233],"ABSSSI":[47,67,235],"IDUs.":[49,155,251],"IDUs":[50,127,169,198,239],"(n":[51,68],"=":[52,69],"389)":[53],"were":[54,72,139,151,164,180,199],"identified":[55],"from":[56,101],"pooled":[58],"phase":[59],"3":[60],"(NCT01170221,":[62],"NCT01421511)":[63],"patients":[65],"with":[66,216,220],"1333).":[70],"Patients":[71],"randomly":[73],"assigned":[74],"to":[75,141],"phosphate":[77],"(200":[78],"mg":[79,87],"once":[80],"daily,":[81,89],"6":[82],"days)":[83],"or":[84],"linezolid":[85,163,205,221,230],"(600":[86],"twice":[88],"10":[90],"days).":[91],"Primary":[92],"endpoint":[93],"was":[94,123,131,186,214,236],"\u2265":[95],"20%":[96],"reduction":[97],"lesion":[99],"area":[100],"baseline":[102],"at":[103,115,178],"48":[104],"-72":[105],"h.":[106],"Secondary":[107],"endpoints":[108],"included":[109],"investigator-assessed":[110],"clinical":[111,157],"microbiological":[113],"response":[114,183],"post-therapy":[117],"evaluation":[118],"(PTE).":[119],"RESULTS:":[120],"Wound":[121],"infection":[122],"more":[124,132,152],"common":[125,133],"(52.2%),":[128],"while":[129,148,208],"cellulitis/erysipelas":[130],"non-IDUs":[135],"(55.9%).":[136],"Most":[137],"due":[140],"Staphylococcus":[142],"aureus":[143],"(IDUs,":[144],"75.2%;":[145],"non-IDUs,":[146,175,241],"85.6%),":[147],"oral":[149],"pathogens":[150],"prevalent":[153],"Early":[156],"success":[158],"rates":[159],"82.5%":[165],"79.6%":[167],"81.3%":[171],"79.3%":[173],"respectively;":[176],"responses":[177],"PTE":[179],"similar.":[181],"Microbiological":[182],"per":[184],"pathogen":[185],"similar":[187,237],"between":[188,201],"groups.":[190],"Rates":[191],"treatment-emergent":[193],"adverse":[194],"events":[195],"(AEs)":[196],"comparable":[200],"(46.2%)":[203],"(47.8%)":[206],"arms,":[207],"lower":[209],"incidence":[210],"gastrointestinal":[212],"AEs":[213],"observed":[215],"(20.3%)":[218],"than":[219],"(25.1%).":[222],"CONCLUSION:":[223],"Efficacy":[224],"supporting":[242],"oxazolidinones":[246],"treating":[248],"ABSSSIs":[249],"FUNDING:":[252],"Merck":[253],"&":[254],"Co.,":[255],"Inc.,":[256],"Kenilworth,":[257],"NJ,":[258],"USA.":[259]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-09-27T00:00:00"}